Global Carbinoxamine Market Insights, Forecast to 2028

Carbinoxamine is an antihistamine and anticholinergic agent. It is used for hay fever, vasomotor rhinitis, mild urticaria, angioedema, dermatographism and allergic conjunctivitis. Carbinoxamine is a histamine antagonist, specifically an H1-antagonist.
Market Analysis and Insights: Global Carbinoxamine Market
Due to the COVID-19 pandemic, the global Carbinoxamine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Tablet accounting for % of the Carbinoxamine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Carbinoxamine market size is valued at US$ million in 2021, while the US and Europe Carbinoxamine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Carbinoxamine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Carbinoxamine include Johnson and Johnson, Endo, Mikart Pharmaceuticals, Cipla, Cosmed Pharmaceutical, Perrigo, Hui Chun Tang Pharma, October Pharma and Mack Rides, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Carbinoxamine Scope and Segment
Carbinoxamine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Carbinoxamine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Tablet
Oral Solution
Segment by Application
Hospital
Drug Store
By Company
Johnson and Johnson
Endo
Mikart Pharmaceuticals
Cipla
Cosmed Pharmaceutical
Perrigo
Hui Chun Tang Pharma
October Pharma
Mack Rides
Abbott
Yung Shin Pharmaceutical
Everest Pharmaceutical
Medical Union Pharmaceuticals
Shyh Dar Pharmaceutical
Tris Pharma
Stanley Pharma
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE